{
    "clinical_study": {
        "@rank": "3385", 
        "brief_summary": {
            "textblock": "The purpose of this study is to see if it is safe and effective to give AIDSVAX B/B or\n      AIDSVAX B/E, two potential HIV vaccines, to HIV-negative volunteers."
        }, 
        "brief_title": "A Study of AIDSVAX B/B and AIDSVAX B/E, Two Possible Vaccines", 
        "condition": "HIV Infections", 
        "condition_browse": {
            "mesh_term": [
                "HIV Infections", 
                "Acquired Immunodeficiency Syndrome"
            ]
        }, 
        "detailed_description": {
            "textblock": "Patients are randomized to 1 of the 2 following arms and administered 1 or 2 injections into\n      the deltoid muscle at 0, 1, 6, and 12 months:\n\n      Arm A: Patients receive 1 of 3 doses of AIDSVAX B/B vaccine (MN rgp120/HIV-1 plus GNE8\n      rgp120/HIV-1) in alum adjuvant.\n\n      Arm B: Patients receive AIDSVAX B/E (MN rgp120/HIV-1 plus A244 rgp120/HIV-1) vaccine in alum\n      adjuvant.\n\n      Patients are evaluated at 1 hr, 3 days, and 14 days after each immunization and at 18 months\n      after the first immunization.\n\n      An interim analysis is performed after all patients receive the second dose (at 1 month)."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Patients must:\n\n        Be HIV-uninfected men and women at low or intermediate risk for HIV-1 infection."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": "120", 
        "firstreceived_date": "November 2, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00002402", 
            "org_study_id": "VAX 002"
        }, 
        "intervention": [
            {
                "intervention_name": "MN rgp120/HIV-1 and GNE8 rgp120/HIV-1", 
                "intervention_type": "Biological"
            }, 
            {
                "intervention_name": "MN rgp120/HIV-1 and A244 rgp120/HIV-1", 
                "intervention_type": "Biological"
            }, 
            {
                "intervention_name": "Aluminum hydroxide", 
                "intervention_type": "Biological"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Aluminum Hydroxide"
        }, 
        "keyword": [
            "HIV-1", 
            "Dose-Response Relationship, Drug", 
            "Acquired Immunodeficiency Syndrome", 
            "AIDS Vaccines", 
            "HIV Seronegativity", 
            "Antigens, Viral", 
            "Alum Compounds"
        ], 
        "lastchanged_date": "June 23, 2005", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Denver", 
                        "country": "United States", 
                        "state": "Colorado", 
                        "zip": "80204"
                    }, 
                    "name": "Dr Frank Judson / Director of Public Health Dept"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Washington", 
                        "country": "United States", 
                        "state": "District of Columbia", 
                        "zip": "20037"
                    }, 
                    "name": "Johns Hopkins Bloomberg School of Public Health"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Boston", 
                        "country": "United States", 
                        "state": "Massachusetts", 
                        "zip": "02115"
                    }, 
                    "name": "Fenway Community Health Ctr"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Saint Louis", 
                        "country": "United States", 
                        "state": "Missouri", 
                        "zip": "63110"
                    }, 
                    "name": "Saint Louis Univ Health Sciences Ctr"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "Phase I/II Trial to Evaluate the Safety and Immunogenicity of AIDSVAX B/B and B/E Vaccines in the United States", 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 1", 
        "reference": {
            "citation": "Mayer K, Judson F, Gorse G, Harro C, Peterson M, Zaharias E, Good J, Shibata R, Lee S, Eastman D, Chernow M, Francis D, Berman P. A phase I/II trial to evaluate the safety and immunogenicity of the AIDSVAX B/B vaccine in the United States (final report). 8th Conf Retro and Opportun Infect. 2001 Feb 4-8 (abstract no 178)"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00002402"
        }, 
        "source": "NIH AIDS Clinical Trials Information Service", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "VaxGen", 
                "agency_class": "Industry"
            }
        }, 
        "study_design": "Endpoint Classification: Safety Study, Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "August 1998"
    }, 
    "geocoordinates": {
        "Dr Frank Judson / Director of Public Health Dept": "39.739 -104.985", 
        "Fenway Community Health Ctr": "42.358 -71.06", 
        "Johns Hopkins Bloomberg School of Public Health": "38.895 -77.036", 
        "Saint Louis Univ Health Sciences Ctr": "38.627 -90.199"
    }
}